Oppenheimer analyst Jeff Jones raised the firm’s price target on Pharming (PHAR) to $41 from $40 and keeps an Outperform rating on the shares after the company announced Q2 results. Moving into the second half of 2025, Oppenheimer anticipates competitive pressure on Ruconest from Ekterly, potentially up to a 20% hit by year-end 2026 as patients try the oral option, its estimates counterbalanced by reduced expenses.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
- Pharming Group Reports Strong Q2 2025 Revenue Growth
- Pharming Group Reports Strong Q2 2025 Financial Results and Business Update
- Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
- Pharming Group to Host Webcast on New APDS Study Findings